Predictors of loss of hepatitis B surface antigen in HIV-infected patients

Table 3 Multivariate Cox regression analysis of factors associated with loss of HBsAg

	Odds ratio (95% CI)	P
ALT baseline
Normal ALT (ref)
Elevated ALT	0.157 (0.013-1.829)	0.139
HCV co-infection
HCV negative (ref)
HCV positive	0.073 (0.002-2.802)	0.160
HIV VL baseline (copies/mL)
HIV VL ≤ 75	3.018 (0.028-325.768)	0.644
HIV VL 76-500	9.195 (0.037-2289.798)	0.431
HIV VL 501-100 000	1.026 (0.009-118.554)	0.991
HIV VL > 100 000 (ref)
HIV VL end of follow up (copies/mL)
HIV VL ≤ 75	1134.708 (0.000-1.43E+151)	0.968
HIV VL 76-500	4403. 835 (0.000-5.55E+151)	0.962
HIV VL 501-100 000	3338.767 (0.000-4.19E+151)	0.963
HIV VL > 100 000 (ref)
CD4 baseline (cells/mm3)
CD4 < 200 (ref)
CD4 200-350	0.983 (0.042-22.809)	0.992
CD4 351-500	0.000 (0.000-1.35E+034)	0.834
CD4 > 500	76.174 (2.233-2598.481)	0.016
CD4 end of follow-up (cells/mm3)
CD4 < 200 (ref)
CD4 200-350	9.113 (0.141-587.310)	0.299
CD4 351-500	0.521 (0.018-15.301)	0.705
CD4 > 500	0.003 (0.000-0.631)	0.034
CD4 gain (cells/mm3)
CD4 gain ≤ 150 (ref)
CD4 gain > 150	2.800 (0.122-64.365)	0.520
HAART
No HAART (ref)
HAART	0.117 (0.004-3.105)	0.199

Data for 226 patients. Data censored at the time of HBsAg loss.